Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

Table 1 Top 20 proteins that differed in preclinical AD from the control group according to CSF t-tau status

Contrast	Cohort	Number of proteins that differ	Top 20 proteins with largest effect size
Preclinical AD with increased t-tau
Proteins with increased concentration relative to CN	EMIF-AD MBD	262	YWHAH, LAMP5, PCSK5, CHI3L1, SMOC1, ADCYAP1, SPP1, GDA, CRYM, TAGLN3, PLXNA2, PCDH8, HPRT1, CPD, GAP43, ENPP5, CAMK2A, PKM, MELTF, NAXE
	ADNI	93	NRGN, PKM, VSNL1, GOT1, ALDOA, SPP1, GOT2, HGF, NEO1, NCSTN, MOG, APLP2, SOD1, BACE1, APP, CHI3L1, FABP3, ENO2, NCAM2, SPON1
Proteins with decreased concentration relative to CN	EMIF-AD MBD	19	S100A6, ADAMDEC1, GPLD1, ANXA5, KNG1, SERPINA4, HSPA1A, IGHV4-30–2, CPB2, IGHV4-30–4, FLNA, IGHV3-30, PRAP1, IGLV3-10, HSPA6, ABI3BP, IGHV2-70D, HSPA7, PON1
	ADNI	2	GOLM1, LEP
Preclinical AD with normal t-tau
Proteins with increased concentration relative to CN	EMIF-AD MBD	36	SLC39A12^b, ADIPOQ^a, ANGPTL7, LGI1^b, CD9^b, KRT24, IFI30^a, TTR^b, FOLR1^b, NCMAP, SLC5A5^b, SELPLG, ENPP2^b, F5^b, CTSA, KRT12, KRT9, SIAE^b, COL15A1, KRT10
	ADNI	3	EDN1, APOE-e4, FGF4^b
Proteins with decreased concentration relative to CN	EMIF-AD MBD	102	HS6ST1, CDH9, ASTN1, PLXNA1, APP, PMP2, STMN3, CDH8, PRKAR1A, GABARAPL2, GALNT6, PITHD1, GALNT1, CPM, MMP17, FAM19A2, CD99, FURIN, TAGLN, CDH12
	ADNI	24	abeta1-40, abeta1-38, ADGRL1, CADM3, NEO1, NPTX1, MCAM, CHGB, PCSK1, NEGR1, L1CAM, UBB, PTPRN, CACNA2D1, TIMP1, PAM, BTD, VEGFA, DAG1, NBL1

T-tau Total tau, CN Control group with normal cognition, normal Aβ_1-42 and normal t-tau
^aProtein associated with Blood Brain Barrier dysfunction
^bProteins with high expression in choroid plexus. Full list of proteins is provided in Data S2, column BK-BN

ISSN: 1750-1326